Reference intervals for plasma L-arginine and the L-arginine: Asymmetric dimethylarginine ratio in the framingham offspring cohort

Journal of Nutrition

Volumn 141, Issue 12, 2011, Pages 2186-2190

  Lüneburg, Nicole ^a   Xanthakis, Vanessa ^b,e   Schwedhelm, Edzard ^a   Sullivan, Lisa M ^b   Maas, Renke ^c   Anderssohn, Maike ^a   Riederer, Ulrich ^d   Glazer, Nicole L ^e   Vasan, Ramachandran S ^e   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C REACTIVE PROTEIN; GLUCOSE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; STABLE ISOTOPE;

ADULT; AMINO ACID BLOOD LEVEL; ANALYTICAL PARAMETERS; ARGININE ASYMMETRIC DIMETHYLARGININE RATIO; ARGININE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TANDEM MASS SPECTROMETRY;

AGED; ARGININE; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; NITRIC OXIDE SYNTHASE; REFERENCE VALUES; TANDEM MASS SPECTROMETRY;

EID: 84855521313     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.148197     Document Type: Article

References (45)

1. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
2. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endotheliumdependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-6.
3. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
4. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87:99-105.
5. Schmidt HH, Nau H, Wittfoht W, Gerlach J, Prescher KE, Klein MM, Niroomand F, Bohme E. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol. 1988;154:213-6.
6. Jeserich M, Münzel T, Just H, Drexler H. Reduced plasma L-arginine in hypercholesterolaemia. Lancet. 1992;339:561.
7. Maas R, Schwedhelm E, Kahl L, Li H, Benndorf R, Lüneburg N, Förstermann U, Böger RH. Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem. 2008;54:292-300.
8. Böger RH, Tsikas D, Bode-Böger SM, Phivthong-Ngam L, Schwedhelm E, Frölich JC. Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-(15) N(2)]-arginine to (15)N-labeled nitrate by gas chromatography-mass spectrometry. Nitric Oxide. 2004;11:1-8.
9. Egan JM, Henderson TE, Bernier M. Arginine enhances glycogen synthesis in response to insulin in 3T3-L1 adipocytes. Am J Physiol. 1995;269:E61-6.
10. Lucotti P, Monti L, Setola E, La Canna G, Castiglioni A, Rossodivita A, Pala MG, Formica F, Paolini G, Catapano AL, et al. Oral l-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism. 2009;58:1270-6.
11. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824-33.
12. Böger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med. 2005;10 Suppl 1:S1-2.
13. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr. 2006;26:203-28.
14. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-5.
15. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:211-9.
16. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem. 2005;51:1268-71.
17. Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Schulze F, Riederer U, Benndorf RA, Boger RH, Vasan RS. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham Offspring Cohort. Clin Chem. 2009;55:1539-45.
18. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281-90.
19. Solberg HE, Lahti A. Detection of outliers in reference distributions: performance of Horn's algorithm. Clin Chem. 2005;51:2326-32.
20. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PWF, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction. Circulation. 2003;107:1486-91.
21. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PWF. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:1251-7.
22. Wilson PWF, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening. JAMA. 1989;262:41-4.
23. Shin S, Fung S-M, Mohan S, Fung H-L. Simultaneous bioanalysis of larginine, l-citrulline, and dimethylarginines by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:467-74.
24. Fallang A, Larsen S, Horsberg TE. Upper susceptibility threshold limits with confidence intervals: a method to identify normal and abnormal population values for laboratory toxicological parameters, based on acetylcholinesterase activities in sea lice. Pest Manag Sci. 2006;62:208-13.
25. Levey AS, Greene T, Schluchter M, Cleary P, Teschan P, Lorenz R, Molitch M, Mitch W, Siebert C, Hall P. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993;4:1159-71.
26. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-600.
27. Walker HA, McGing E, Fisher I, Boger RH, Bode-Boger SM, Jackson G, Ritter JM, Chowienczyk PJ. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol. 2001;38:499-505.
28. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med. 2005;10 Suppl 1:S49-57.
29. Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med. 2002;7:213-25.
30. Maas R, Wenske S, Zabel M, Ventura R, Schwedhelm E, Steenpass A, Klemm H, Noldus J, Boger RH. Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. Eur Urol. 2005;48:1004-11, discussion 1011-2.
31. Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J, Geny B. Chronic L-arginine supplementation enhances endurance exercise tolerance in heart failure patients. Int J Sports Med. 2006;27:567-72.
32. Howell K, Costello CM, Sands M, Dooley I, McLoughlin P. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296:L1042-50.
33. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality: an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009;60:481.
34. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:273-83.
35. Böger RH. The pharmacodynamics of L-arginine. J Nutr. 2007;137: S1650-5.
36. Böger RH. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care. 2008;11:55-61.
37. Kalousova M, Kielstein JT, Hodkova M, Zima T, Dusilova-Sulkova S, Martens-Lobenhoffer J, Bode-Boger SM. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif. 2006;24:439-44.
38. Wu G, Bazer F, Davis T, Kim S, Li P, Marc Rhoads J, Carey Satterfield M, Smith S, Spencer T, Yin Y. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37:153-68.
39. Wascher TC, Graier WF, Dittrich P, Hussain MA, Bahadori B, Wallner S, Toplak H. Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Invest. 1997;27:690-5.
40. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-75.
41. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:1557-64.
42. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005;10:14-23.
43. Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, Schulze F, Boger RH. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65:51-9.
44. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, et al. l-Arginine therapy in acute myocardial infarction. JAMA. 2006;295:58-64.
45. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. LArginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. 2007;116:188-95